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Barbara Muz1, Feda Azab1, Mark Fiala2, Justin King2, Daniel Kohnen2, William E. Fogler3, Ted Smith3, John L. Magnani3,
Ravi Vij2 and Abdel Kareem Azab1

Dear Editor,
Multiple myeloma (MM) is a plasma cell malignancy
localized in the bone marrow (BM) characterized by
continuous metastasis. MM remains incurable, despite
the improved overall survival of MM patients due to
clinically introduced novel treatments such as proteasome
inhibitors (bortezomib and carﬁlzomib) and immunomodulatory drugs (IMiDs; lenalidomide)1.
The complex cross-talk between MM cells and the
tumor microenvironment (TME) facilitates tumor progression and therapy resistance2. Adhesion molecules
such as selectins3,4 and C-X-C chemokine receptor type 4
(CXCR4, CD184)5–7 play pivotal roles in advancement of
MM, suggesting that these molecules could be targeted to
reduce metastasis and overcome drug resistance. Elevated
CXCR4 expression enables MM cells’ dissemination from
the primary tumor site to the peripheral blood (PB) and
further to a new BM site attracted by chemokines such as
stromal-derived growth factor-1 (SDF-1). Homing of MM
is initiated through interaction between ligands present
on MM cells such as cutaneous lymphocyte-associated
antigen (CLA; role of which is not well described in
MM)3,8 and adhesion molecules E- and P-selectin
expressed on vascular endothelium, which induce rolling, adhesion, and extravasation. Most of cancer therapies
consist of targeting the MM cells directly; however,
recently disrupting MM interactions with the TME
through inhibiting adhesion of cancer cells to the TME or
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hindering the homing of already circulating tumor cells
thus preventing metastasis have been suggested as therapeutic strategies3–5,7,8. In this study, we tested the effect
of blocking E-selectin alone using GMI-12718 and
blocking both E-selectin and CXCR4 using GMI-13599 on
TME disruption in order to sensitize MM cells to
chemotherapy.
First, analysis of CXCR4, CLA, and E-selectin mRNA
expression in CD138+ plasma cells isolated from newly
diagnosed MM patients using the Gene Expression Omnibus database10 showed (mean ± s.e.m.) 18,223.19 ± 452.04,
3472.67 ± 118.01, and 42.16 ± 2.01, respectively (Fig. 1a).
Interestingly, CLA expression in CD138+ plasma cells was
the highest among patients with MM (3472.67 ± 118.01)
compared to monoclonal gammopathy of undetermined
signiﬁcance (2459.96 ± 270.13) and healthy donors
(1910.85 ± 107.72) (Fig. 1b). This data suggests that CXCR4
mRNA is highly expressed in newly diagnosed MM patients
and that CLA mRNA expression signiﬁcantly increases with
MM advancement. We have previously demonstrated that
MM progression and dissemination was hypoxia dependent, and hypoxic MM cells had improved cell trafﬁcking6,
increased tumor initiation, and induced drug resistance
contributing to minimal residual disease and relapse7,11.
Natoni et al. demonstrated that the CLA was increased in
hypoxic MM cells implying disease progression, and CLA
expression was further augmented in MM cells from
relapsed/refractory patients compared to newly diagnosed
patients8. These results suggest that CLA undergoes
dynamic changes with MM development and could
potentially be a biomarker of disease progression and drug
resistance. However, we found that CLA expression was
negligible and restricted to a small subpopulation of MM
cells (1.3% MM.1S, 0.9% H929 and 6.3% U266) (Fig. 1c)
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Fig. 1 CXCR4 mRNA is highly expressed in primary multiple myeloma (MM) cells, CLA expression increases with myeloma progression;
CXCR4 protein expression is widely present in MM cells, while E-selectin protein is highly expressed in endothelial cells and stromal cells.
Gene expression of E-selectin (ID 206211_at), CLA (ID 209879_at), and CXCR4 (ID 217028_at) mRNA analyzed in CD138+ bone marrow plasma cells
isolated from newly diagnosed MM patients (n = 559) using the Gene Expression Omnibus database [log scale] (a). The expression of CLA mRNA in
CD138+ plasma cells harvested from healthy donors (n = 22), MGUS patients (n = 44), and newly diagnosed MM patients (n = 559) using the Gene
Expression Omnibus database [log scale] analyzed using one-way analysis of variance test (b). Percentage of CLA+- and CXCR4+-positive cells in MM
cell lines demonstrated as mean ± s.e.m (c). CLA and C-X-C chemokine receptor type 4 (CXCR4) protein expression levels in MM cell lines
demonstrated as RMFI (mean ± s.e.m.). Results are obtained from three independent biological replicates and repeated minimum in three separate
experiments (d). Expression of cell surface proteins including E-selectin, CLA, and CXCR4 in endothelial cells (human umbilical vein endothelial cells),
malignant stromal cells (MSP-1), and normal stromal cells (HS-5) demonstrated as the percentage of positive cells (e) and RMFI (f). Results are
representative of at least three independent experiments and demonstrated as mean ± s.e.m. CLA cutaneous lymphocyte-associated antigen, MGUS
monoclonal gammopathy of undetermined signiﬁcance, RMFI relative mean ﬂuorescent intensity

possibly due to lack of TME and hypoxic conditions. In all,
85% of MM.1S, 44% of H929, and 97% of U266 cells were
positive for CXCR4 (Fig. 1c), with the relative mean ﬂuorescent intensity (RMFI) of 5.8, 10.6, and 12.9, respectively
(Fig. 1d). Regarding MM-supporting cells, 96% of human
Blood Cancer Journal

umbilical vein endothelial cells (HUVECs), 70% of MSP-1,
and 80% of HS-5 cells were E-selectin positive (Fig. 1e) with
an RMFI of 25, 12, and 17, respectively (Fig. 1f). These cells
had insigniﬁcant levels of CLA; however, CXCR4 was present in HUVECs, MSP-1, and HS-5 at 57, 55, and 29% of
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cells, respectively (Fig. 1e), with an RMFI of 6, 3.5, and 2.9,
respectively (Fig. 1f), conﬁrming high expression of Eselectin and CXCR4 in endothelial and stromal cells.
Next, we tested the effect of GMI-1271 (E-selectin
antagonist) and GMI-1359 (E-selectin and CXCR4 dual
antagonist) on the ability of MM cells to migrate to
conditioned media. Pretreatment of MM.1S cells with
GMI-1271 signiﬁcantly reduced chemotaxis to HS-5 and
MSP-1 media by ≤20%, while GMI-1359 greatly reduced
chemotaxis to SDF-1-enriched-, HS-5-, and MSP-1derived media by 47, 53, and 61%, respectively (Fig. 2a).
U266, but not MM.1S and H929, cell adhesion to
HUVECs was signiﬁcantly reduced following GMI-1271
treatment, possibly due to the highest percentage of CLApositive cells, while GMI-1359 treatment signiﬁcantly
decreased adhesion of MM.1S, H929, and U266 to
HUVECs by 38, 53, and 42%, respectively (Fig. 2b). Furthermore, in order to recapitulate the MM extravasation
through the endothelium to the BM, we performed a
trans-endothelial migration in vitro, where labeled MM
cells were added on top of HUVECs and trans-migrated
toward stromal cells cultured at the bottom of a Boyden
chamber. MM cells cultured overnight in hypoxia, which
was shown to increase CXCR46 and CLA8 expression,
decreased the hypoxia-induced trans-endothelial migration of MM cells to stroma when pretreated with GMI1271 or GMI-1359 by 17% and 40%, respectively (Fig. 2c).
Similarly, GMI-1359 pretreatment caused a signiﬁcant
MM.1S cell retention in the circulation and prevented
extravasation at 90 min postintravenous injection in vivo
(Fig. 2d). Since GMI-1359 blocks not only CXCR4 but
also E-selectin, we performed an experiment where either
MM cells or mouse endothelium or both were pretreated
with GMI-1359 before monitoring MM homing to the
BM (Fig. 2e). When mice were injected with GMI-1359
intravenously 30 min prior to the injection of labeled MM
cells, homing of the MM cells was inhibited by ~40%
compared to vehicle-treated mice. Moreover, when the
cells were pretreated with GMI-1359 prior injection, their
homing to the BM was almost completely abrogated,
regardless whether the mice endothelium was pretreated
with GMI-1359 or not. Interestingly, U266 homed the
least compared to MM.1S and H929.
Next, we examined the effect of GMI-1271 in combination with lenalidomide on MM.1S survival cultured
with or without MSP-1 stromal cells in vitro. We found
that GMI-1271 alone did not affect MM.1S survival, and
co-culture with stroma signiﬁcantly induced drug
resistance to lenalidomide, while combination treatment
with both drugs signiﬁcantly overcame the stromainduced lenalidomide resistance (Fig. 2f). Similar results
were observed for H929 survival co-cultured with
HUVECs (Supplementary Fig. 1A). Consequently, we
tested MM tumor progression in a human xenograft
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mouse model, where SCID mice were inoculated with
MM.1S-Luc and tumor progression was monitored
using bioluminescent imaging. GMI-1271 and lenalidomide as single agents delayed tumor growth by 40%
and 35%, respectively, while combined lenalidomide and
GMI-1271 signiﬁcantly delayed tumor growth by 55%
and 64% at days 14 and 21, respectively, compared to
vehicle (Fig. 2g). Next, we tested GMI-1271 in combination with carﬁlzomib (CFZ) on MM.1S survival
in vitro, which signiﬁcantly overcame the stromainduced CFZ resistance (Fig. 2h). Similar results were
obtained for H929 and U266 co-cultured with stroma,
treated with GMI-1271 in combination with CFZ and
bortezomib (BTZ) (Supplementary Fig. 1). Subsequently, we examined mice survival using a syngeneic
5TGM1 disseminated mouse model and demonstrated
signiﬁcantly extended median survival in groups treated
with vehicle, GMI-1271, CFZ, or combination, which
were 36.5, 36.5, 40, and 49.5 days, respectively (Fig. 2i).
Next, combination treatment with GMI-1359 and CFZ
studied in vitro demonstrated that GMI-1359 signiﬁcantly overcame the stroma-induced resistance to
CFZ (Fig. 2j). Similar results were obtained for H929 and
U266 co-cultured with stroma and treated with GMI1359 in combination with CFZ or BTZ (Supplementary
Fig. 2), as well as using a three-dimensional tissueengineered bone marrow with MM.1S co-cultured with
accessory cells recapitulating TME (Supplementary Fig.
3). Subsequently, median survival of mice inoculated
with 5TGM1 cells treated with vehicle, GMI-1359, CFZ,
or combination was signiﬁcantly extended to 32.5, 34,
38.5, and 49 days, respectively (Fig. 2k). These results
imply that E-selectin and/or CXCR4 antagonists (GMI1271 and GMI-1359) were sufﬁcient in retaining MM
cells in the circulation, inferring longer MM exposure to
chemotherapies and improved MM response to proteasome inhibitors and IMiDs. Our results are in
agreement with others showing that both GMI-1271 and
GMI-1359 disrupted the TME and mobilized cancer
cells into the circulation more effectively and gradually
over long periods of time compared to CXCR4 inhibition alone (using Plerixafor)8,12–14. Again, sustaining the
presence of tumor cells in the blood by inhibiting their
re-entry into the BM provides a longer window to target
these cells in the circulation.
In conclusion, majority of MM patients relapse and
become refractory to therapy, due to the supportive TME
that assists cancer with drug resistance and metastasis1,2.
Herein, we disrupted the interaction between MM cells
and the TME with GMI-1271 and GMI-1359 by
decreasing CXCR4 and E-selectin-mediated adhesion and
chemotaxis of MM cells, which sensitized them to therapy
in vitro, and by inhibiting the homing process thus
extending the exposure of MM cells to chemotherapies
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Fig. 2 (See legend on next page.)
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(see ﬁgure on previous page)
Fig. 2 GMI-1271 and GMI-1359 disrupt the TME–multiple myeloma (MM) cell interaction by decreasing C-X-C chemokine receptor type 4
(CXCR4) and E-selectin-mediated adhesion and chemotaxis of MM cells, which sensitizes MM cells to therapy in vitro, and by inhibiting
the homing process thus extending the exposure of MM cells to chemotherapies, delaying tumor growth, and improving mice survival
in vivo. Percentile of vehicle-, GMI-1271-, or GMI-1359-treated MM.1S migrated toward conditioned media derived from either MSP-1 or HS-5 or 10%
fetal bovine serum/RPMI1640 media enriched with stromal-derived growth factor-1 (50 nM) and normalized to vehicle-treated MM.1S (a). Percentile
of vehicle-, GMI-1271-, or GMI-1359-treated MM.1S, H929, and U266, which adhered to human umbilical vein endothelial cells (HUVECs), normalized
to vehicle-treated MM cells (b). Percentile of vehicle-, GMI-1271-, or GMI-1359-treated MM.1S trans-migrated through HUVECs to MSP-1 stromal cells
and normalized to vehicle-treated MM cells (c). Percentile of vehicle-, GMI-1271-, or GMI-1359-treated MM.1S cells, which remained in the circulation
of mice at 90 min post-MM injection (d). Percentile of vehicle- or GMI-1359-pretreated H929, MM.1S, and U266 cells, which homed to the BM in
vehicle- or GMI-1359-pretreated mice (i.e., injected intravenously with 40 mg/kg of GMI-1359 30 min before MM injection) counted in the BM by ﬂow
cytometry demonstrated as mean ± s.e.m. (e). Survival of MM.1S cells treated with or without GMI-1271 (20 µM) and lenalidomide (1 µM) for 24 h
cultured with or without stromal cells (recapitulating TME) tested by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay (f).
Tumor progression of MM.1S-GFP-Luc cells injected into SCID mice treated with: (1) vehicle, (2) GMI-1271 (40 mg/kg), (3) lenalidomide (25 mg/kg),
and (4) a combination of lenalidomide (25 mg/kg) and GMI-1271 (40 mg/kg) followed weekly using bioluminescence imaging normalized to Day 0
posttreatment initiation (g). Survival of MM.1S cells treated with or without GMI-1271 (20 µM) and carﬁlzomib (CFZ; 5 nM) for 24 h cultured with or
without stromal cells (recapitulating TME) tested by MTT assay (h). Percentile of MM-bearing mice survival receiving: (1) vehicle, (2) GMI-1271 (40 mg/
kg), (3) CFZ (3 mg/kg), and (4) a combination of GMI-1271 (40 mg/kg) and CFZ (3 mg/kg) followed daily, and demonstrated as a Kaplan–Meier curve.
The survival of mice receiving CFZ as a single drug or GMI-1271 in combination with CFZ was signiﬁcantly extended compared to vehicle (p = 0.0274
and p = 0.0001, respectively); additionally, GMI-1271 in combination with CFZ signiﬁcantly extended mice survival compared to CFZ only (p = 0.0006)
(i). Survival of MM.1S cells treated with or without GMI-1359 (20 µM) and CFZ (5 nM) for 24 h cultured with or without stromal cells (recapitulating
TME) tested by MTT assay (j). Percentile of MM-bearing mice survival receiving: (1) vehicle, (2) GMI-1359 (40 mg/kg), (3) CFZ (3 mg/kg), and (4) a
combination of GMI-1359 (40 mg/kg) and CFZ (3 mg/kg) followed daily, and demonstrated as a Kaplan–Meier curve. The survival of mice receiving
CFZ as a single drug or GMI-1359 in combination with CFZ was signiﬁcantly extended compared to vehicle (p = 0.0002 and p = 0.0001, respectively).
In addition, GMI-1359 in combination with CFZ signiﬁcantly extended mice survival compared to CFZ only (p = 0.014) (k). In vitro studies were
performed in quadruplets, repeated minimum three times, and demonstrated as mean ± s.e.m. with statistical signiﬁcance for p values <0.05
calculated using unpaired Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001). Statistical analysis for in vivo experiments was performed using two-way
analysis of variance. BM bone marrow, TME tumor microenvironment

and improving mice survival in vivo. These results provide
preclinical basis for future clinical trials to test the ability
of dual inhibition of E-selectin and CXCR4 to sensitize
relapsed/refractory MM patients to therapy. Notably, a
completed Phase 1/2 clinical trial in acute myeloid leukemia patients using GMI-1271 showed high remission
rates and improved overall survival with favorable
safety15, and a Phase 1 clinical trial is being performed on
MM patients (NCT02811822). Currently, GMI-1359 is
being evaluated in a Phase 1 clinical trial in healthy
volunteers (NCT02931214).
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